Vermont Disclosure Act

Vermont law 33 V.S.A. §2005a mandates that pharmaceutical manufacturers disclose to Vermont physicians and other prescribers the average wholesale price (AWP) of drugs they market within the state as well as the prices of other drugs in the same therapeutic class. Under Vermont law, "therapeutic class" is defined as the therapeutic class listed in the 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists (available at http://www.ashp.org).

Incyte Corporation has listed these therapeutic class prices in Long Form Disclosures as required under Vermont Law.

JAKAFI (ruxolitinib)

Long Form Disclosure

Short Form Disclosure

PEMAZYRE (pemigatinib)

Long Form Disclosure

Short Form Disclosure

Colorado Disclosure Act

Colorado law HB 19-1131 requires pharmaceutical manufacturers, when engaging in prescription drug marketing, to provide the wholesale acquisition cost (WAC) of the drug to Colorado prescribers. Under Colorado law, the names of generic prescription drugs (if available) from the same therapeutic class (i.e., same or similar mechanism of action used to treat a specific condition) shall also be provided. 

JAKAFI (ruxolitinib)

JAKAFI (ruxolitinib) Disclosure Form

PEMAZYRE (pemigatinib)

PEMAZYRE (pemigatinib) Disclosure Form